Crescendo Bioscience, Inc.
Crescendo Bioscience, Inc. is developing a broad range of quantitative, objective molecular diagnostic tests to enable Rheumatologists to more effectively manage patients with autoimmune and inflammatory diseases. The Company is initially focused on rheumatoid athritis (RA), a debilitating, chronic disease affecting over 1.5 million in the USA and more than 2 million in Europe. Crescendo Bioscience is building a comprehensive understanding of the biology underlying RA, including the characterization of protein and gene expression biomarkers, to provide molecular staging of the disease and guidance for the treatment of individual patients. Crescendo plans to provide comprehensive diagnostic, prognostic, staging, therapy selection and monitoring capabilities to improve outcomes throughout the continuum of care. All testing will be performed at our specialized, CLIA-licensed laboratory in California.